JeanOlivier Racine - Outset Medical Chief Officer
| OM Stock | USD 0.76 0.03 4.11% |
Insider
JeanOlivier Racine is Chief Officer of Outset Medical
| Age | 42 |
| Address | 3052 Orchard Drive, San Jose, CA, United States, 95134 |
| Phone | 669 231 8200 |
| Web | https://www.outsetmedical.com |
Outset Medical Management Efficiency
The company has Return on Asset (ROA) of (0.2683) % which means that for every 100 dollars spent on asset, it generated a loss of $0.2683. This is way below average. Likewise, it shows a return on total equity (ROE) of (1.4102) %, which implies that it produced no returns to current stockholders. Outset Medical's management efficiency ratios could be used to measure how well Outset Medical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to drop to -0.58. In addition to that, Return On Capital Employed is likely to drop to -0.69. At this time, Outset Medical's Debt To Assets are very stable compared to the past year. As of the 22nd of November 2024, Fixed Asset Turnover is likely to grow to 7.34, while Return On Tangible Assets are likely to drop (0.58).Similar Executives
| Showing other executives | INSIDER Age | ||
| Jared Oasheim | CVRx Inc | 40 | |
| Janet Byk | Inari Medical | N/A | |
| Donald Middlebrook | Nevro Corp | 69 | |
| Joseph Powers | Si Bone | 64 | |
| Dena Truelove | Inari Medical | N/A | |
| Mark Quick | Orthofix Medical | N/A | |
| Barbara Schwarzentraub | CONMED | 53 | |
| Richard Carter | Nevro Corp | 53 | |
| Reay Brown | Sight Sciences | N/A | |
| BA Chemistry | Orthofix Medical | 63 | |
| Paul Badawi | Sight Sciences | 49 | |
| Andre Marquette | Neuropace | N/A | |
| John Ordway | Sight Sciences | N/A | |
| Rebecca Kuhn | Neuropace | 63 | |
| Mark Saxton | Neuropace | 59 | |
| Laverne Council | CONMED | 59 | |
| Michael Favet | Neuropace | 54 | |
| Sri Radhakrishnan | Pulmonx Corp | N/A | |
| Paul Verrastro | CVRx Inc | 61 | |
| Georgia Melenikiotou | Inspire Medical Systems | 61 | |
| Shanna Cottiosmanski | CONMED | 47 | |
Management Performance
| Return On Equity | -1.41 | ||||
| Return On Asset | -0.27 |
Outset Medical Leadership Team
Elected by the shareholders, the Outset Medical's board of directors comprises two types of representatives: Outset Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Outset. The board's role is to monitor Outset Medical's management team and ensure that shareholders' interests are well served. Outset Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Outset Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stacey Porter, Chief Officer | ||
| Mark MS, Chief Officer | ||
| Steven Williamson, Chief Officer | ||
| Marc Nash, Senior RD | ||
| Leslie Trigg, CEO President | ||
| John JD, General Secretary | ||
| Martin Vazquez, Chief Officer | ||
| John Brottem, General Secretary | ||
| JeanOlivier Racine, Chief Officer | ||
| James Mazzola, Head Relations | ||
| Michael MD, Chief Officer | ||
| Nicole Shannon, Director Communications | ||
| Tonya Saffer, Head Access | ||
| Nabeel Ahmed, Principal CFO |
Outset Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Outset Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.41 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (1.23) % | ||||
| Operating Margin | (0.83) % | ||||
| Current Valuation | 66.4 M | ||||
| Shares Outstanding | 52.54 M | ||||
| Shares Owned By Insiders | 2.11 % | ||||
| Shares Owned By Institutions | 55.14 % | ||||
| Number Of Shares Shorted | 3.35 M | ||||
| Price To Book | 0.84 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Outset Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Outset Stock, please use our How to Invest in Outset Medical guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Outset Medical. If investors know Outset will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Outset Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.74) | Revenue Per Share 2.235 | Quarterly Revenue Growth (0.06) | Return On Assets (0.27) | Return On Equity (1.41) |
The market value of Outset Medical is measured differently than its book value, which is the value of Outset that is recorded on the company's balance sheet. Investors also form their own opinion of Outset Medical's value that differs from its market value or its book value, called intrinsic value, which is Outset Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Outset Medical's market value can be influenced by many factors that don't directly affect Outset Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Outset Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Outset Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Outset Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.